ESC Premium Access

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Congress Presentation

About the speaker

Professor Yong Huo

Peking University First Hospital, Beijing (China)
0 follower

56 more presentations in this session

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

Speaker: Doctor C. Becker (Wuppertal, DE)

Thumbnail

Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics

Speaker: Doctor S. Frechen (Leverkusen, DE)

Thumbnail

Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study

Speaker: Doctor C. Ballantyne (Houston, US)

Thumbnail

The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population

Speaker: Doctor D. Radenkovic (Greater London, GB)

Thumbnail

Adherence to high-intensity statin therapy after acute coronary syndrome and its impact on patient outcome

Speaker: Doctor P. Sulzgruber (Vienna, AT)

Thumbnail

Access the full session

Pharmacology and Pharmacotherapy ePosters

Speakers: Professor Y. Huo, Doctor C. Becker, Doctor S. Frechen, Doctor C. Ballantyne, Doctor D. Radenkovic...
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb